Stephen Brand

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5750837/publications.pdf

Version: 2024-02-01

19 papers	960 citations	516215 16 h-index	794141 19 g-index
20 all docs	20 docs citations	20 times ranked	1184 citing authors

#	Article	IF	Citations
1	N-myristoyltransferase inhibitors as new leads to treat sleeping sickness. Nature, 2010, 464, 728-732.	13.7	272
2	Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 9318-9323.	3.3	119
3	Discovery of a Novel Class of Orally Active Trypanocidal N-Myristoyltransferase Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 140-152.	2.9	102
4	Lead Optimization of a Pyrazole Sulfonamide Series of Trypanosoma brucei N-Myristoyltransferase Inhibitors: Identification and Evaluation of CNS Penetrant Compounds as Potential Treatments for Stage 2 Human African Trypanosomiasis. Journal of Medicinal Chemistry, 2014, 57, 9855-9869.	2.9	57
5	Pharmacological Validation of N-Myristoyltransferase as a Drug Target in Leishmania donovani. ACS Infectious Diseases, 2019, 5, 111-122.	1.8	55
6	Development of a Fluorescence-based Trypanosoma cruzi CYP51 Inhibition Assay for Effective Compound Triaging in Drug Discovery Programmes for Chagas Disease. PLoS Neglected Tropical Diseases, 2015, 9, e0004014.	1.3	43
7	A Molecular Hybridization Approach for the Design of Potent, Highly Selective, and Brain-Penetrant N-Myristoyltransferase Inhibitors. Journal of Medicinal Chemistry, 2018, 61, 8374-8389.	2.9	41
8	Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis. Journal of Medicinal Chemistry, 2019, 62, 1180-1202.	2.9	33
9	The proteasome as a target for protozoan parasites. Expert Opinion on Therapeutic Targets, 2019, 23, 903-914.	1.5	32
10	Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi. Journal of Medicinal Chemistry, 2017, 60, 7284-7299.	2.9	31
11	Validation of N-myristoyltransferase as Potential Chemotherapeutic Target in Mammal-Dwelling Stages of Trypanosoma cruzi. PLoS Neglected Tropical Diseases, 2016, 10, e0004540.	1.3	25
12	Scaffold-Hopping Strategy on a Series of Proteasome Inhibitors Led to a Preclinical Candidate for the Treatment of Visceral Leishmaniasis. Journal of Medicinal Chemistry, 2021, 64, 5905-5930.	2.9	25
13	Reaction hijacking of tyrosine tRNA synthetase as a new whole-of-life-cycle antimalarial strategy. Science, 2022, 376, 1074-1079.	6.0	25
14	Chemical Validation of Methionyl-tRNA Synthetase as a Druggable Target in Leishmania donovani. ACS Infectious Diseases, 2017, 3, 718-727.	1.8	22
15	Development of Smallâ€Molecule Trypanosoma brucei Nâ€Myristoyltransferase Inhibitors: Discovery and Optimisation of a Novel Binding Mode. ChemMedChem, 2015, 10, 1821-1836.	1.6	20
16	Design of proteasome inhibitors with oral efficacy in vivo against Plasmodium falciparum and selectivity over the human proteasome. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	19
17	Design and Synthesis of Brain Penetrant Trypanocidal N-Myristoyltransferase Inhibitors. Journal of Medicinal Chemistry, 2017, 60, 9790-9806.	2.9	14
18	Discovery of Potent and Fast-Acting Antimalarial Bis-1,2,4-triazines. Journal of Medicinal Chemistry, 2021, 64, 4150-4162.	2.9	14

#	Article	IF	Citations
19	Optimisation of 2-(N-phenyl carboxamide) triazolopyrimidine antimalarials with moderate to slow acting erythrocytic stage activity. Bioorganic Chemistry, 2021, 115, 105244.	2.0	11